Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | MMEL1 | Q495T6 | 1/20 | 0.38 |
| ▸ | CASP3 | P42574 | 1/20 | 0.38 |
| ▸ | LTA4H | P09960 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21978221 | 1.00 | MEN1 (0.41) | MEN1KMT2AL3MBTL1ALDH1A1MMEL1 | |
| SCHEMBL21978223 | 1.00 | MEN1 (0.41) | MEN1KMT2AL3MBTL1ALDH1A1MMEL1 | |
| SCHEMBL21978444 | 0.94 | CASP3 (0.37) | MEN1KMT2AL3MBTL1ALDH1A1CASP3 | |
| SCHEMBL21978441 | 0.94 | CASP3 (0.37) | MEN1KMT2AL3MBTL1ALDH1A1CASP3 | |
| SCHEMBL21994849 | 0.86 | CASP3 (0.42) | KMT2ACASP3 | |
| SCHEMBL21994848 | 0.86 | CASP3 (0.42) | KMT2ACASP3 | |
| SCHEMBL30065486 | 0.86 | CASP3 (0.42) | KMT2ACASP3 | |
| SCHEMBL21978458 | 0.81 | CASP3 (0.36) | MEN1KMT2ACASP3 | |
| SCHEMBL21978457 | 0.81 | CASP3 (0.36) | MEN1KMT2ACASP3 | |
| SCHEMBL21979043 | 0.81 | FFAR2 (0.37) | MEN1KMT2AL3MBTL1CASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11813306-B2 | Cyclic tetramer compounds as proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors for the treatment of metabolic disorders | NOVARTIS AG (CH) | 2023-11-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11813306-B2 | Cyclic tetramer compounds as proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors for the treatment of metabolic disorders | PCSK9, PCSK7, PCSK6 | MEN1 337/4885KMT2A 2933/4885L3MBTL1 2963/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.